Summary
This is a machine-generated summary.
(1) The National Healthcare Security Administration and the National Health Commission recently issued a notice titled "Several Measures to Support the High-Quality Development of Innovative Medicines". The notice aims to promote the high-quality development of innovative medicines and improve the accessibility and affordability of these medicines for patients.
(2) To achieve this goal, the notice proposes several measures, including:
(3) 1. Expanding the scope of innovative medicines covered by the national medical insurance program, with a focus on medicines that have significant clinical benefits and are priced reasonably. 2. Improving the reimbursement standards for innovative medicines, including increasing the reimbursement rate for certain medicines and reducing the co-payment burden on patients. 3. Enhancing the evaluation and approval process for innovative medicines, with a focus on improving the efficiency and transparency of the review process. 4. Encouraging the development of generic and biosimilar versions of innovative medicines, to increase competition and reduce prices. 5. Supporting the development of innovative medicines for rare diseases and other unmet medical needs. 6. Improving the pricing mechanism for innovative medicines, with a focus on ensuring that prices are reasonable and reflect the value of the medicines. 7. Enhancing the management of innovative medicines, including improving the monitoring of safety and efficacy and the management of adverse events.
(4) The notice also emphasizes the importance of public participation and feedback in the development and implementation of these measures. It encourages the public to provide suggestions and comments on the measures and to participate in the evaluation and approval process for innovative medicines.
(5) The notice is expected to have a significant impact on the development and accessibility of innovative medicines in China, and will likely lead to increased investment and innovation in the pharmaceutical industry.